Boston Life Sciences (US) files for Parkinson's agent:
This article was originally published in Clinica
Executive Summary
Boston Life Sciences (US) plans to begin a clinical trial with the Parkinson's disease radioimaging agent, Altropane, before the end of this year. An IND (investigational new drug) application has been filed with the FDA. The radiolabelled molecule binds to the dopamine transporter in areas of the brain affected by the disease. Use of Altropane is expected to provide earlier diagnosis of Parkinson's, enabling earlier therapeutic intervention, says chief scientific officer Marc Lanser. Apart from later-stage products obtained through the merger with Greenwich Pharmaceuticals, Altropane is Boston Life Sciences' first product to enter clinical development.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.